Malcolm, Javian C.
Falzone, Nadia
Gains, Jennifer E.
Aldridge, Matthew D.
Mirando, David
Lee, Boon Q.
Gaze, Mark N.
Vallis, Katherine A. http://orcid.org/0000-0003-4672-5683
Funding for this research was provided by:
Cancer Research UK (C5255/A15935, C7893/ A28990)
Article History
Received: 18 May 2021
Accepted: 24 January 2022
First Online: 28 March 2022
Declarations
:
: The LuDO trial was conducted in accordance with the recommendations of guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964, amended at the 48th World Medical Association General Assembly, Somerset West, Republic of South Africa, October 1996; and with the Research Governance Framework for Health and Social Care, UK law, and the applicable UK Statutory Instruments. The trial received a favorable opinion from the National Research Ethics Service’s London–Hampstead Research Ethics Committee; a Clinical Trial Authorization from the Medicines and Healthcare products Regulatory Agency (MHRA); approval from the Administration of Radioactive Substances Advisory Committee (ARSAC); and local Research and Development approval. Parents or legal guardians of patients gave written informed consent for LuDO trial entry.
: Not applicable.
: The authors declare that they have no competing interests.